» Articles » PMID: 17768418

TGFbeta is Responsible for Skin Tumour Infiltration by Macrophages Enabling the Tumours to Escape Immune Destruction

Overview
Publisher Wiley
Date 2007 Sep 5
PMID 17768418
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Infiltration of skin tumours by macrophages is an important step in tumour progression, although the mechanisms of macrophage recruitment to the tumour mass and the subsequent effects on tumour growth are poorly understood. Transfecting a murine regressing skin tumour with the gene for transforming growth factor (TGF)beta enabled the tumours to grow progressively in vivo thus allowing us to study the role of this cytokine in tumour growth. Flow cytometry was used to show that TGFbeta-mediated tumour progression was accompanied by an increase in tumour-associated macrophages (TAM) and a decrease in tumour-infiltrating dendritic cells (DCs). TAM in TGFbeta-secreting tumours expressed lower levels of major histocompatibility complex II and CD86 compared to DC in control tumours and had a high phagocytic capacity as measured by uptake of latex beads in vivo. Indeed, TGFbeta was directly responsible not only for the enhanced macrophage phagocytosis but also altering the ratio of antigen-presenting cells to favour macrophages over DC. Our results demonstrate that TGFbeta recruitment and retention of macrophages at the tumour site enable effective tumour evasion of the host immune system and reinforces the need to target TGFbeta in human cancer immunotherapy trials.

Citing Articles

Current status of research on the mechanisms of tumor-associated macrophages in esophageal cancer progression.

Tang Y, Shi T, Lin S, Fang T Front Oncol. 2024; 14:1450603.

PMID: 39678502 PMC: 11638059. DOI: 10.3389/fonc.2024.1450603.


Mesenchymal Stem Cells in Cancer Therapy.

Baran Z, Cetinkaya M, Baran Y Adv Exp Med Biol. 2024; 1474():149-177.

PMID: 39470980 DOI: 10.1007/5584_2024_824.


Correlation of Immunomodulatory Cytokines with Tumor Volume and Cerebrospinal Fluid in Vestibular Schwannoma Patients.

Becker A, Scholle L, Klause C, Staege M, Strauss C, Otto M Cancers (Basel). 2024; 16(17).

PMID: 39272860 PMC: 11394145. DOI: 10.3390/cancers16173002.


Advances in mesenchymal stem cells therapy for tendinopathies.

Mao X, Zhang X, Yao Z, Mao H Chin J Traumatol. 2023; 27(1):11-17.

PMID: 38052701 PMC: 10859297. DOI: 10.1016/j.cjtee.2023.11.002.


Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives.

Said S, Ibrahim W Pharmaceutics. 2023; 15(4).

PMID: 37111629 PMC: 10141036. DOI: 10.3390/pharmaceutics15041143.